Pluvicto + Checkpoint Inhibitor Combination
Metastatic Castration-Resistant Prostate Cancer
Sponsor Novartis
1,200 Enrollment Target
200 Trial Sites
5 Countries
June 2028 Est. Completion
About This Trial
Radioligand therapy combined with pembrolizumab for enhanced tumor killing.
Primary Endpoints
- Overall survival
- Radiographic progression-free survival
Latest Update
February 2026
Interim analysis triggered early. Results expected Q2 2026 with potential accelerated approval pathway.